Clinical trial
Docetaxel and Thalidomide as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
NCT00114192
Study timeline
Study start (unknown)2004-06-01Date precision: month
Registry last updated2010-02-01
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Lung Cancerunresolved
Interventions
docetaxelDRUG · verified · RxNorm: docetaxel
thalidomideDRUG · verified · RxNorm: thalidomide
Sponsors & collaborators
University of Virginialead sponsor
National Cancer Institute (NCI)collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00114192 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.